Regulatory milestones

Galectin Therapeutics Inc. (NASDAQ:GALT) rose $1.21 (22%) to $6.78 on Monday after FDA granted Fast Track designation to GR-MD-02 to treat non-alcoholic steatohepatitis (NASH) with advanced hepatic fibrosis. The galectin-3 (LGALS3) and galectin-1 (LGALS1) inhibitor is in Phase I testing, with data expected by year end.